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Abstract
Background—Previous studies examining the teratogenic effects of antiherpetic medications 
have found no associations for birth defects overall but have not examined the risk of specific 
birth defects.
Methods—The National Birth Defects Prevention Study ascertains population-based cases with 
birth defects and live-born controls without birth defects in ten states across the United States for 
the purpose of identifying potential teratogenic risk factors. Mothers of cases and controls are 
interviewed within two years of their estimated date of delivery about demographic, medical and 
behavioral factors before and during pregnancy. This analysis examined the possible association 
between use of antiherpetic medications (acyclovir, valacyclovir or famciclovir) during early 
pregnancy and gastroschisis, a birth defect of the abdominal wall.
Results—The mothers of 1.1% (n=10) of 941 gastroschisis cases and 0.3% (n=27) of 8339 
controls reported antiherpetic medication use during the month before conception through the 
third month of pregnancy. The adjusted odds ratios for such use in relation to gastroschisis were 
4.68 (95% confidence interval [1.65, 13.28]) and 4.68 [1.15, 19.03] among women with and 
without self-reported genital herpes, respectively, when compared to women without antiherpetic 
use or herpes. Among women reporting no antiherpetic medication use, the odds ratio for self-
reported genital herpes in relation to gastroschisis was 3.00 [1.58, 5.68].
Conclusions—Our study raises the possibility of an increased risk of gastroschisis due to either 
antiherpetic medication use during early pregnancy or the underlying genital herpes infection for 
which it was indicated.
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Gastroschisis is a birth defect in which abdominal contents are located outside of the body 
wall and can lead to serious neonatal and long-term morbidity.1,2 The pathogenesis of 
gastroschisis is not known but the critical susceptibility window occurs during the first 
trimester.3 The increasing prevalence of gastroschisis within the United States (US) 4-7 
suggests environmental factors may be important causes of this disease.3,8 However, the 
aetiology of gastroschisis remains elusive.
Previous studies have found no evidence for an increased risk of birth defects overall due to 
antiherpetic medication use.9-13 However, in an exploratory analysis, one recent Danish 
study observed a strong but imprecise association between first trimester antiherpetic 
medication use and abdominal wall defects in the aggregate (prevalence odds ratio 3.58, 
95% confidence interval [0.84, 15.27]).9 Antiherpetic medications are nucleoside analogues 
that disrupt DNA replication and pharmacokinetic studies have shown that acyclovir crosses 
the placenta,12,14,15 therefore it is possible that antiherpetic medications could affect 
embryogenesis, a process that involves rapid mitotic divisions and DNA replication.
We examined the association between antiherpetic medication use and the risk of 
gastroschisis in the National Birth Defects Prevention Study (NBDPS), which includes the 
largest sample of gastroschisis cases with maternal exposure information in the US.
METHODS
Since 1997, the NBDPS has been ascertaining population-based cases with birth defects and 
live-born controls without birth defects in 10 US states for the purpose of identifying 
potential teratogenic risk factors.16 Cases were identified from birth defect registries and 
were classified by clinical geneticists using standardized criteria.17 Controls were infants 
born without any major structural malformation and were selected randomly from the source 
population.
Within two years of their estimated date of delivery, mothers took part in a computer-
assisted telephone interview about demographic, medical and behavioral factors during 
pregnancy and the three months before conception. Interviews from women with an 
estimated date of delivery before January 2008 were included in this analysis. Institutional 
review boards at the Centers for Disease Control and Prevention and at each participating 
center have approved the study.
Gastroschisis cases
Cases included fetuses/infants diagnosed with gastroschisis during physical examination, 
surgery, or autopsy, or by prenatal high resolution ultrasound with view of the umbilicus.18
Antiherpetic medication use
Women were asked about occurrences of and treatments for infections and sexually 
transmitted infections. Women who reported medication use were asked about timing and 
frequency of use. Antiherpetic medications included acyclovir, valacyclovir or famciclovir.
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Reports of “herpes” illnesses were assumed to be genital herpes; reports of “cold sores” or 
“oral herpes” were classified separately as oral herpes. A priori, genital herpes was 
considered a confounder in the analysis. Antiherpetic medication is also indicated for other 
types of infections, therefore any reports of these infections were investigated jointly as a 
potential confounder.11 Additional potential confounders included maternal factors 
previously associated with antiherpetic medication use and/or gastroschisis as well as 
reported infections and medication use during the first trimester.8
Regression Analysis
We estimated the odds ratios of antiherpetic medication use in relation to gastroschisis with 
logistic regression models. Antiherpetic medication use during early pregnancy (the month 
before conception through the third month of pregnancy) was the primary exposure. 
Analyses examined women with and without self-reported herpes using a common reference 
group of women without antiherpetic medication use or herpes.
Assessment of recall bias
We performed two sensitivity analyses to explore possible recall bias. First, we explored the 
risk of gastroschisis in relation to antiherpetic medication use exclusively outside of early 
pregnancy, when there is no biologically plausible effect on the development of 
gastroschisis. If this estimate was elevated, it could indicate the primary model’s effect 
estimate might be elevated due to recall bias. Second, we repeated the analysis between 
early pregnancy antiherpetic medication use and gastroschisis using as controls infants with 
malformations other than gastroschisis, assuming mothers’ recall accuracy would be similar 
for both groups.
RESULTS
There were 941 gastroschisis cases and 8339 controls included in the analysis. Case mothers 
were more likely than controls to be young and to report periconceptional smoking, lower 
pre-pregnancy body mass index (BMI), illicit drug use and genital herpes (Table 1). Overall, 
use of antiherpetic medication during pregnancy and in the three months before conception 
was 1.5% (14/941) among case and 0.9% (71/8339) among control mothers. The monthly 
prevalence of antiherpetic medication use was higher among case than control mothers for 
all pregnancy months (Figure 1).
Use of antiherpetic medication during early pregnancy was associated with an increased risk 
of gastroschisis among women with and without self-reported genital herpes (adjusted odds 
ratio [AOR] 4.68, 95% confidence interval [1.65, 13.28] and 4.68, [1.15, 19.03], 
respectively) when compared to women with neither genital herpes nor antiherpetic 
medication use (Table 2). Among women reporting no antiherpetic medication use, the AOR 
for self-reported genital herpes in relation to gastroschisis was 3.00 [1.58, 5.68]. Models 
were adjusted for maternal age and BMI; additional adjustment for other potential 
confounders, including other infections that might be treated with antiherpetics, did not 
substantially change estimates of association.
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Assessment of recall bias
Antiherpetic medication use exclusively outside of early pregnancy among women without 
genital herpes showed a possible elevated association with gastroschisis (AOR 2.69, [0.81, 
8.93]); among women with genital herpes the OR for such use could not be calculated (0% 
among cases vs. 0.3% among controls). When the malformed controls were substituted for 
the non-malformed controls in the analysis, the association between early pregnancy 
antiherpetic medication use and gastroschisis remained elevated for both women with and 
without genital herpes (AOR 9.36 [3.50, 25.08] and 3.01 [0.96, 9.42], respectively) when 
compared to women with neither genital herpes nor antiherpetic medication use.
COMMENTS
Antiherpetic medication use during early pregnancy was uncommon but appeared to be 
associated with a four-fold increased risk for gastroschisis when compared to the risk among 
women reporting neither genital herpes nor antiherpetic medication use. Similar associations 
were observed for both women with and without self-reported genital herpes. That recall 
bias is unlikely to account for these association is supported by the fact that when the 
analysis was performed using malformed controls, risks remained elevated. It should be 
noted that antiherpetic medication use was rare in our study population (<1% prevalence), 
resulting in estimates of association that were imprecise and suggesting our study findings 
could be the result of random error. Notably, the elevated risk associated with early 
pregnancy antiherpetic mediation use was similar in magnitude to that associated with 
untreated genital herpes, suggesting that this underlying infection may be confounding the 
antiherpetic-gastroschisis association we observed.
Although several studies have examined the risk of birth defects overall in relation to 
antiherpetic medication during pregnancy and have found no association, no study has 
specifically focused on gastroschisis.9-13 Studies in rats have found teratogenic effects of 
high doses of acyclovir administered during organogenesis but no abdominal wall defects 
have been noted.19
Explanation for our findings
In an effort to disentangle the separate effects of antiherpetic medication use and genital 
herpes infection, we created mutually-exclusive categories with women who reported 
neither exposure as the comparison group. The elevated ORs for antiherpetic medication use 
and for genital herpes without such use could represent positive associations for both 
exposures. However, it is important to consider exposure measurement in this study. While 
reports of genital herpes were probably correct, women not reporting genital herpes may 
indeed have been diagnosed with genital herpes but did not report that in the interview. 
Women were not specifically asked about antiherpetic medication use or genital herpes in 
this study and both exposures were reported by smaller proportions of women (0.9% and 
1.2%, respectively) than in another case-control birth defects study, the Slone Birth Defects 
Study20 (2.3% and 2.1%, respectively), which did specifically ask about medication use for 
genital herpes (based on an unpublished analysis by KAA and MMW). While 6% of women 
reported their antiherpetic medication use for indications other than genital herpes, 36% did 
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not describe the infection treated, though it seems unlikely that an antiherpetic would be 
prescribed in the absence of an indication. With likely misclassification of both our primary 
exposure and its indication, assessment of their separate effects is further complicated. One 
possibility is that the medication use is a marker of underlying infection and the elevated 
ORs for such use represent an association with infection only. If this is the case, then the 
elevated OR for use outside the etiologic window might also represent an association with 
the herpes infection itself, rather than recall bias.
The NBDPS includes the largest sample of gastroschisis cases with maternal exposure 
information in the US, utilizes specific gastroschisis classification criteria, and collects 
information on a variety of maternal factors both before and during pregnancy. The results 
of our study suggest that antiherpetic medication use during pregnancy, or the infection for 
which it was indicated, may be associated with an increased risk of gastroschisis. This 
finding points to a possible infectious cause of gastroschisis and should direct future 
research into that arena.21 Specific information regarding antiherpetic medication use 
(including actual use patterns and indicating infection), genital herpes outbreak details, and 
serological testing for HSV types 1 and 2 and other herpes infections would allow for better 
classification of exposure and enhanced control for confounding by indication in future 
studies.
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Distribution of self-reported antiherpetic medication use among gastroschisis cases and 
controls by pregnancy month and standardized to age distribution in cases among 
participants of the National Birth Defects Prevention Study, 1997-2007
Abbreviations: “B”= months before conception, and “P”= months after conception
Antiherpetic medication exposure prevalence was 1.5% (14/941) among gastroschisis cases 
and 0.9% (71/8339) among controls.
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Table 1
Maternal and pregnancy characteristics of gastroschisis cases and controls participating in the National Birth 
Defects Prevention study, 1997-2007
Gastroschisis cases (n=941) Non-malformed controls
(n=8339)









TOTAL 742 78.9 199 21.1 2772 33.2 5567 66.8
Maternal age at delivery
  13-19 years 363 48.9 0 0.0 856 30.9 0 0.0
  20-24 years 379 51.1 0 0.0 1916 69.1 0 0.0
  25-29 years 0 0.0 136 68.3 0 0.0 2290 41.1
  30-50 years 0 0.0 63 31.7 0 0.0 3277 58.9
Maternal race
  Non-Hispanic White 361 48.7 122 61.3 1282 46.2 3664 65.8
  Non-Hispanic Black 59 8.0 15 7.5 438 15.8 493 8.9
  Hispanic 252 34.0 49 24.6 889 32.1 1032 18.5
  Asian/Pacific Islander 26 3.5 4 2.0 40 1.4 205 3.7
  Native American 7 0.9 0 0.0 18 0.6 24 0.4
  Other a 37 5.0 9 4.5 105 3.8 147 2.6
Body mass index (kg/m2)
  Underweight (12 to
 <18.5)
73 9.8 7 3.5 229 8.3 204 3.7
  Normal (18.5 to <25) 479 64.6 122 61.3 1331 48.0 2781 50.0
  Overweight/obese
 (≥25 )
170 22.9 65 32.7 1058 38.2 2395 43.0
  Missing 20 2.7 5 2.5 154 5.6 187 3.4
Periconceptional smoking
  Yes 260 35.0 74 37.2 763 27.5 777 14.0
  No b 482 65.0 125 62.8 2005 72.3 4789 86.0
Illicit drug use before or
during pregnancy
  Yes 177 23.9 36 18.1 415 15.0 520 9.3
  No 565 76.1 163 81.9 2357 85.0 5047 90.7
Self-reported genital
herpes
  Yes 13 1.8 9 4.5 28 1.0 70 1.3
  No 729 98.2 190 95.5 2744 99.0 5497 98.7
Other indicating
infections c
  Yes 4 0.5 0 0.0 7 0.3 10 0.2
  No 738 99.5 199 100 2765 99.7 5557 99.8
a
Includes 3 women missing maternal race information
b
Includes 5 women missing maternal smoking information
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c
Includes oral herpes, mononucleosis and chicken pox/shingles
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Table 2
Multivariable logistic regression modeling of antiherpetic medication use on the risk of gastroschisis by 
pregnancy exposure window among participants of National Birth Defects Prevention Study, 1997-2007
Gastroschisis cases Controls Unadjusted Adjusteda
Genital Herpes Antiherpetic use 
exposure windowb
n % n % OR 95% CI OR 95% CI
All All 941 100.0 8339 100.0
No No antiherpetic use 911 96.8 8213 98.5 Reference
No Antiherpetic use during early pregnancy 4 0.4 10 0.1 3.61 [1.13, 11.53] 4.68 [1.15, 19.03]
No
Antiherpetic use exclusively 
outside of early
pregnancy
4 0.4 18 0.2 2.00 [0.68, 5.93] 2.69 [0.81, 8.93]
Yes No antiherpetic use 16 1.7 55 0.7 2.62 [1.50, 4.60] 3.00 [1.58, 5.68]
Yes Antiherpetic use during early pregnancy 6 0.6 17 0.2 3.18 [1.25, 8.10] 4.68 [1.65, 13.28]
Yes
Antiherpetic use exclusively 
outside of early
pregnancy
0 0.0 26 0.3 Not modeled Not modeled
a
The covariates for adjusted models included maternal age at delivery (13-19, 20-24, 25-29 [reference], 30-50 years) and BMI before conception 
(<18.5, 18.5-25 [reference], >25, missing)
b
Early pregnancy was defined as the month before conception through the third month of pregnancy.
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